scispace - formally typeset
Journal ArticleDOI

Combined Lifestyle Modification and Metformin in Obese Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-controlled, Double-blind Multicentre Study

Reads0
Chats0
TLDR
Metformin does not improve weight loss or menstrual frequency in obese patients with PCOS, and weight loss alone through lifestyle changes improves menstrual frequency.
Abstract
Metformin therapy reportedly benefits women with polycystic ovary syndrome (PCOS). Its effect is presumably based on lowering serum insulin levels. Metformin inhibits glucose production in the liver and also enhances insulin sensitivity at the cellular level. This prospective, randomized, double-blind, placebo-controlled study evaluated the effects of lifestyle change and metformin therapy in 143 women with PCOS who were oligomenorrheic or amenorrheic and had a body mass index (BMI) greater than 30 kg/m2. All patients received standard dietary advice and were placed on an individualized high-carbohydrate, low-fat diet. Metformin, given in a dose of 850 mg twice daily, was compared with placebo over 6 months. The 69 patients placed on metformin and the 74 given placebo had similar characteristics at baseline and had been infertile for similar periods. Menstrual cycles became significantly more frequent in both metformin-treated and placebo patients. The median improvement was one cycle per 6 months. Reductions in body weight and BMI were documented in both groups. None of these parameters differed significantly between the actively treated and placebo patients. In neither group did insulin sensitivity or lipid profiles change significantly. Patients given metformin had significant reductions in waist circumference and the free androgen index. On logistic regression analysis, considering metformin therapy, percentage of weight loss, initial BMI, and age, only the percentage weight loss correlated with improved menstrual function. There were 2 pregnancies in each group. In this trial, metformin did not enhance weight loss or menstrual frequency in obese patients with PCOS compared with placebo patients. Only weight loss during dietary management made menstruation more frequent.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.

TL;DR: Evaluation of women with PCOS should exclude alternate androgen-excess disorders and risk factors for endometrial cancer, mood disorders, obstructive sleep apnea, diabetes, and cardiovascular disease.
Journal ArticleDOI

The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

TL;DR: Polycystic ovary syndrome seems to arise as a complex trait that results from the interaction of diverse genetic and environmental factors, heritable factors include PCOM, hyperandrogenemia, insulin resistance, and insulin secretory defects.
Journal ArticleDOI

Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.

TL;DR: The uses of metformin are analyzed not only for the treatment of all PCOS-related disturbances such as menstrual disorders, anovulatory infertility, increased abortion, or complicated pregnancy risk, hyperandrogenism, endometrial, metabolic and cardiovascular abnormalities, but also for the prevention of the syndrome.
Journal ArticleDOI

Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus

TL;DR: The mechanisms underlying the plasma glucose level-lowering effects of metformin (1,1-dimethylbiguanide) still remain incompletely understood as discussed by the authors. But, the role of AMPK has been challenged and might only account for indirect changes in hepatic insulin sensitivity.
Journal ArticleDOI

Cardiometabolic Aspects of the Polycystic Ovary Syndrome

TL;DR: The aim of the present review is to discuss and to summarize the current knowledge, focusing on the alterations of cardiometabolic factors in women with PCOS, to facilitate finding therapeutic targets that should ameliorate not only ovarian dysfunction but also the various cardiometric alterations related to the syndrome.
References
More filters
Journal ArticleDOI

Homeostasis model assessment : insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man

TL;DR: The correlation of the model's estimates with patient data accords with the hypothesis that basal glucose and insulin interactions are largely determined by a simple feed back loop.
Journal ArticleDOI

Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.

TL;DR: It is concluded that QUICKI is an index of insulin sensitivity obtained from a fasting blood sample that may be useful for clinical research.
Journal ArticleDOI

Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.

TL;DR: The HOMA can be reliably used in large-scale or epidemiological studies in which only a fasting blood sample is available to assess insulin sensitivity and there is good agreement between the two methods in the categorization of subjects according to insulin sensitivity.
Journal ArticleDOI

Maternal obesity and pregnancy outcome: a study of 287 213 pregnancies in London

TL;DR: Maternal obesity carries significant risks for the mother and foetus and the risk increases with the degree of obesity and persists after accounting for other confounding demographic factors.
Journal ArticleDOI

Maternal morbid obesity and the risk of adverse pregnancy outcome

TL;DR: Maternal morbid obesity in early pregnancy is strongly associated with a number of pregnancy complications and perinatal conditions.
Related Papers (5)